Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alamar Biosciences, Inc.ALMR · Entity 1791 | Director | April 20, 2026 | April 21, 2026 |
| Outset Medical, Inc.OM · Entity 7026 | Chief Financial Officer | June 24, 2021 | June 25, 2021 |
| VERACYTE, INC.VCYT · Entity 2018 | Chief Financial Officer | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alamar Biosciences, Inc.
Report date April 20, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-01-14 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-20 · Other · Disposed 140,612 · Balance 0 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F2: Twenty-five percent of the shares subject to the option vest on January 15, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-01-14 | Direct | 140,612 |
Reported balance
After 2026-04-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-20 · Other · Acquired 140,612 · Balance 140,612 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F2: Twenty-five percent of the shares subject to the option vest on January 15, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock.
F2: Twenty-five percent of the shares subject to the option vest on January 15, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date.
Outset Medical, Inc.
Report date June 24, 2021 · Filed June 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,597 |
Ending reported balance
After 2021-06-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-06-24 · Exercise / conversion · Acquired 16,727 · Balance 30,324 Row 2 · 2021-06-24 · Sale · Disposed 16,727 · Balance 13,597 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $50.32 to $51.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.25 · Expires 2029-09-10 | Direct | 77,745 |
Reported balance
After 2021-06-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-06-24 · Exercise / conversion · Disposed 16,727 · Balance 77,745 F3: This option vests 25% on June 3, 2020 and then in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020.
F2: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $50.32 to $51.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: This option vests 25% on June 3, 2020 and then in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through the applicable vesting date.
VERACYTE, INC.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 166,025 |
Ending reported balance
After 2026-09-04 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-02 · Tax withholding · Disposed 3,603 · Balance 169,677 F1: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale. Row 2 · 2026-09-04 · Sale · Disposed 2,477 · Balance 167,200 F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F3: Represents weighted average sales price. Sale prices for the transactions range from $42.49 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Row 3 · 2026-09-04 · Sale · Disposed 1,175 · Balance 166,025 F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F4: Represents weighted average sales price. Sale prices for the transactions range from $43.51 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.
F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.
F3: Represents weighted average sales price. Sale prices for the transactions range from $42.49 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
F4: Represents weighted average sales price. Sale prices for the transactions range from $43.51 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date February 19, 2025 · Filed February 19, 2025
Section 16 reporting ended · disclosed 2025-02-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 1
1 source rowRow 1 · 2025-02-19 · Other · Disposed 9,684 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2022 Filed May 27, 2022 16:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 2,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015884 · form4.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,370 F1 · shares: Represents RSUs granted on May 26, 2022, to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2023 annual meeting. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:40 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 37,773 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001384101-22-000050 · wf-form4_164668921354091.xml · derivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,773 Underlying: Common Stock · 37,773 shares Expires 2032-03-03 F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2023, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:40 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 20,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000050 · wf-form4_164668921354091.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,728 F1 · kind: Restricted stock units awarded on March 3, 2022 vest 25% on March 2, 2023 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 20:51 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $36.59 | $0.00 |
DisclosureSEC source: 0001384101-21-000127 · wf-form4_162681424157518.xml · derivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2031-07-19 F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on July 19, 2022, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 20:51 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000127 · wf-form4_162681424157518.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 F1 · kind: Restricted stock units (RSUs) awarded on July 19, 2021, which vest 25% on September 2, 2022 and 1/16 on each quarterly anniversary thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 20:02 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,727 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001484612-21-000035 · edgardoc.xml · derivative · entry 3 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,745 Underlying: Common Stock · 16,727 shares Expires 2029-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests 25% on June 3, 2020 and then in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 20:02 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 16,727 | $50.72 | $848,373.37 |
DisclosureSEC source: 0001484612-21-000035 · edgardoc.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,597 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $50.32 to $51.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 20:02 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 16,727 | $6.25 | $104,543.75 |
DisclosureSEC source: 0001484612-21-000035 · edgardoc.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 19:45 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 1,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004431 · primarydocument.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,950 F1 · shares: Represents Restricted Stock Units (RSUs) that vest 1/3 on each of the first, second and third anniversary of the grant date. Read SEC document |
| May 25, 2021 Filed May 26, 2021 21:18 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,727 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001484612-21-000010 · edgardoc.xml · derivative · entry 3 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,472 Underlying: Common Stock · 16,727 shares Expires 2029-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests 25% on June 3, 2020 and then in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| May 25, 2021 Filed May 26, 2021 21:18 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 16,727 | $45.11 | $754,534.90 |
DisclosureSEC source: 0001484612-21-000010 · edgardoc.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,597 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $44.61 to $45.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 25, 2021 Filed May 26, 2021 21:18 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 16,727 | $6.25 | $104,543.75 |
DisclosureSEC source: 0001484612-21-000010 · edgardoc.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 22:43 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,727 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0000905148-21-000407 · form4.xml · derivative · entry 4 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,199 Underlying: Common Stock · 16,727 shares Expires 2029-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vests 25% on June 3, 2020, and then in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 22:43 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 8,228 | $56.89 | $468,055.54 |
DisclosureSEC source: 0000905148-21-000407 · form4.xml · nonDerivative · entry 3 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,597 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $56.79 to $57.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3). Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 22:43 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 8,499 | $56.33 | $478,756.32 |
DisclosureSEC source: 0000905148-21-000407 · form4.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,825 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $55.79 to $56.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2). Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 22:43 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 16,727 | $6.25 | $104,543.75 |
DisclosureSEC source: 0000905148-21-000407 · form4.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 11:00 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,727 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001140361-21-010380 · form4.xml · derivative · entry 4 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,926 Underlying: Common Stock · 16,727 shares Expires 2029-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: This Form 4 corrects the exercise price previously reported as $6.24 on the Form 3 filed on September 14, 2020. F1 · derivative.exercise_date: This option vests 25% on June 3, 2020, and then in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 11:00 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 13,135 | $50.16 | $658,902.83 |
DisclosureSEC source: 0001140361-21-010380 · form4.xml · nonDerivative · entry 3 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,597 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $49.68 to $51.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3). Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 11:00 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 3,592 | $49.11 | $176,414.97 |
DisclosureSEC source: 0001140361-21-010380 · form4.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,732 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $48.62 to $49.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2). Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 11:00 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 16,727 | $6.25 | $104,543.75 |
DisclosureSEC source: 0001140361-21-010380 · form4.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:10 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantStock Option (Right to Buy) · Derivative | 27,037 | $0.00 Strike: $25.89 | $0.00 |
DisclosureSEC source: 0001140361-21-008971 · form4.xml · derivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,037 Underlying: Common Stock · 27,037 shares Expires 2031-03-14 F2 · derivative.exercise_date: This option vests 25% on March 15, 2022, and then in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:10 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 13,597 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-008971 · form4.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,597 F1 · shares: Represents restricted stock units ("RSU") granted to the reporting person on March 15, 2021. Each RSU represents a contingent right to receive one share of common stock. These RSUs shall vest 25% on March 15, 2022, then quarterly over three years on each February 15th, May 15th, August 15th and November 15th, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 19:17 UTC Amendment | Outset Medical, Inc. OM · Entity 7026 | GrantStock Option (Right to Buy) · Derivative | 27,037 | $0.00 Strike: $50.01 | $0.00 |
DisclosureSEC source: 0001140361-21-009053 · form4.xml · derivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,037 Underlying: Common Stock · 27,037 shares Expires 2031-03-14 F2 · derivative.exercise_price: This Form 4 amendment is being filed to correct the exercise price. F1 · derivative.exercise_date: This option vests 25% on March 15, 2022, and then in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.